Nanoliposomal irinotecan plus fluorouracil and folinic acid in irinotecan-pretreated vs. -naive pancreatic cancer patients: A retrospective cohort study

被引：0
|
作者：
Schoenlein, M. [1 ]
Stein, A. [1 ,2 ]
Tintelnot, J. [1 ]
Nilsson, S. [1 ]
Reichelt, R. [3 ]
Borchardt, J. [3 ]
Schnell, R. [4 ]
Goekkurt, E. [1 ,2 ]
Bokemeyer, C. [1 ]
Sinn, M. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin Onkol Hamatol & Knochenmarktr, Abt Pneumol, Hamburg, Germany
[2] Hematol Oncol Practice Hamburg HOPE, Hamburg, Germany
[3] Onkotrakt AG, Hamburg, Germany
[4] Pioh Koln Nord Studien GbR, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep601
引用
收藏
页码：224 / 225
页数：2
相关论文
共 50 条
  • [41] Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study
    Keum, Jiyoung
    Lee, Hee Seung
    Park, Chan Su
    Kim, Jeehoon
    Jang, Wonjoon
    Shin, Kyung In
    Kang, Huapyong
    Lee, Sang Hoon
    Jo, Jung Hyun
    Jang, Sung Ill
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Cho, Jae Hee
    Bang, Seungmin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [42] Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients:The ELSIE study
    Robert Lim
    Seock-Ah Im
    Ruey-Kuen Hsieh
    Tsz Kok Yau
    Anthony Bonaventura
    Arkom Cheirsilpa
    Regina Esser
    Matthias Mueser
    Suresh Advani
    World Journal of Gastroenterology, 2011, 17 (14) : 1879 - 1888
  • [43] Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study
    Lim, Robert
    Sun, Yan
    Im, Seock-Ah
    Hsieh, Ruey-Kuen
    Yau, Tsz Kok
    Bonaventura, Anthony
    Cheirsilpa, Arkom
    Esser, Regina
    Mueser, Matthias
    Advani, Suresh
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (14) : 1879 - 1888
  • [44] Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
    Shibuki, Taro
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Nakazawa, Junichi
    Arima, Shiho
    Fukahori, Masaru
    Miwa, Keisuke
    Okabe, Yoshinobu
    Koga, Futa
    Ueda, Yujiro
    Kubotsu, Yoshihito
    Makiyama, Akitaka
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Nishikawa, Kazuo
    Komori, Azusa
    Otsu, Satoshi
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Oda, Hisanobu
    Kawahira, Machiko
    Arita, Shuji
    Honda, Takuya
    Taguchi, Hiroki
    Tsuneyoshi, Kengo
    Kawaguchi, Yasunori
    Fujita, Toshihiro
    Sakae, Takahiro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Shirakawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [45] Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
    Ulrich-Pur, H
    Raderer, M
    Kornek, GV
    Schüll, B
    Schmid, K
    Haider, K
    Kwasny, W
    Depisch, D
    Schneeweiss, B
    Lang, F
    Scheithauer, W
    BRITISH JOURNAL OF CANCER, 2003, 88 (08) : 1180 - 1184
  • [46] Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
    H Ulrich-Pur
    M Raderer
    G Verena Kornek
    B Schüll
    K Schmid
    K Haider
    W Kwasny
    D Depisch
    B Schneeweiss
    F Lang
    W Scheithauer
    British Journal of Cancer, 2003, 88 : 1180 - 1184
  • [47] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [48] Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
    Chiu, Tai-Jan
    Yang, Shih-Hung
    Chiu, Sz-Chi
    Hsueh, Shun-Wen
    Chiang, Nai-Jung
    Li, Chung-Pin
    Bai, Li-Yuan
    Cheng, Fu-Ming
    Chuang, Shih-Chang
    Shan, Yan-Shen
    Chan, De-Chuan
    Chen, Li-Tzong
    Yen, Chia-Jui
    Peng, Cheng-Ming
    Su, Yung-Yeh
    Chen, Yen-Yang
    Chen, Jen-Shi
    Chou, Wen-Chi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (06) : 670 - 681
  • [49] Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer:: A phase II study
    Endlicher, E.
    Troppmann, M.
    Kullmann, A.
    Goelder, S.
    Herold, T.
    Herfarth, H.
    Grossmann, J.
    Schlottmann, K.
    Kullmann, F.
    ONCOLOGY, 2007, 72 (5-6) : 279 - 284
  • [50] Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
    Harada, Kazuaki
    Yamamura, Takahiro
    Muto, Osamu
    Nakamura, Michio
    Sogabe, Susumu
    Sawada, Kentaro
    Nakano, Shintaro
    Yagisawa, Masataka
    Muranaka, Tetsuhito
    Dazai, Masayoshi
    Tateyama, Miki
    Kobayashi, Yoshimitsu
    Kato, Sosuke
    Hatanaka, Kazuteru
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Sakata, Yuh
    Sakamoto, Naoya
    Komatsu, Yoshito
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
12345